Brain function in Duchenne muscular dystrophy

被引:223
|
作者
Anderson, JL
Head, SI
Rae, C
Morley, JW [1 ]
机构
[1] Univ New S Wales, Sch Physiol & Pharmacol, Sydney, NSW 2052, Australia
[2] Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia
关键词
dystrophin; CNS; mdx;
D O I
10.1093/brain/awf012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is the second most commonly occurring genetically inherited disease in humans. It is an X-linked condition that affects approximately one in 3300 live male births. It is caused by the absence or disruption of the protein dystrophin, which is found in a variety of tissues, most notably skeletal muscle and neurones in particular regions of the CNS. Clinically DMD is characterized by a severe pathology of the skeletal musculature that results in the premature death of the individual. An important aspect of DMD that has received less attention is the role played by the absence or disruption of dystrophin on CNS function. In this review we concentrate on insights into this role gained from investigation of boys with DMD and the genetically most relevant animal model of DMD, the dystrophin-deficient mdx mouse. Behavioural studies have shown that DMD boys have a cognitive impairment and a lower IQ (average 85), whilst the mdx mice display an impairment in passive avoidance reflex and in short-term memory. In DMD boys, there is evidence of disordered CNS architecture, abnormalities in dendrites and loss of neurones, all associated with neurones that normally express dystrophin. In the mdx mouse, there have been reports of a 50% decrease in neurone number and neural shrinkage in regions of the cerebral cortex and brainstem. Histological evidence shows that the density of GABA(A) channel clusters is reduced in mdx Purkinje cells and hippocampal CA1 neurones. At the biochemical level, in DMD boys the bioenergetics of the CNS is abnormal and there is an increase in the levels of choline-containing compounds, indicative of CNS pathology. The mdx mice also display abnormal bioenergetics, with an increased level of inorganic phosphate and increased levels of choline-containing compounds. Functionally, DMD boys have EEG abnormalities and there is some preliminary evidence that synaptic function is affected adversely by the absence of dystrophin. Electrophysiological studies of mdx mice have shown that hippocampal neurones have an increased susceptibility to hypoxia. These recent findings on the role of dystrophin in the CNS have implications for the clinical management of boys with DMD.
引用
收藏
页码:4 / 13
页数:10
相关论文
共 50 条
  • [1] Brain metabolism is abnormal in the mdx model of Duchenne muscular dystrophy
    Tracey, I
    Dunn, JF
    Radda, GK
    BRAIN, 1996, 119 : 1039 - 1044
  • [2] Brain metabolite composition in relation to cognitive function and dystrophin mutations in boys with Duchenne muscular dystrophy
    Kreis, Roland
    Wingeier, Kevin
    Vermathen, Peter
    Giger, Elisabeth
    Joncourt, Franziska
    Zwygart, Karin
    Kaufmann, Franz
    Boesch, Chris
    Steinlin, Maja
    NMR IN BIOMEDICINE, 2011, 24 (03) : 253 - 262
  • [3] Duchenne muscular dystrophy: recent insights in brain related comorbidities
    Vaillend, Cyrille
    Aoki, Yoshitsugu
    Mercuri, Eugenio
    Hendriksen, Jos
    Tetorou, Konstantina
    Goyenvalle, Aurelie
    Muntoni, Francesco
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [4] Challenges in Duchenne muscular dystrophy
    Davies, KE
    NEUROMUSCULAR DISORDERS, 1997, 7 (08) : 482 - 486
  • [5] Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy
    Shieh, Perry B.
    NEUROTHERAPEUTICS, 2018, 15 (04) : 840 - 848
  • [6] The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy
    Alexander, W. M.
    Smith, M.
    Freeman, B. J. C.
    Sutherland, L. M.
    Kennedy, J. D.
    Cundy, P. J.
    EUROPEAN SPINE JOURNAL, 2013, 22 (02) : 411 - 416
  • [7] The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy
    W. M. Alexander
    M. Smith
    B. J. C. Freeman
    L. M. Sutherland
    J. D. Kennedy
    P. J. Cundy
    European Spine Journal, 2013, 22 : 411 - 416
  • [8] Gene therapy for Duchenne muscular dystrophy
    Suzuki, Naoki
    Miyagoe-Suzuki, Yuko
    Takeda, Shin'ichi
    FUTURE NEUROLOGY, 2007, 2 (01) : 87 - 96
  • [9] The Duchenne muscular dystrophy gene and cancer
    Jones, Leanne
    Naidoo, Michael
    Machado, Lee R.
    Anthony, Karen
    CELLULAR ONCOLOGY, 2021, 44 (01) : 19 - 32
  • [10] Impending therapies for Duchenne muscular dystrophy
    Partridge, Terence A.
    CURRENT OPINION IN NEUROLOGY, 2011, 24 (05) : 415 - 422